|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Ochsner Health System, Louisiana’s largest non-profit academic healthcare system, and Pfizer Inc (PFE) have entered into a multi-year strategic alliance to develop innovative models for clinical trials. Through this partnership, Pfizer and Ochsner — through its innovation lab, innovationOchsner (iO), in partnership with Ochsner Research — will explore ways to enhance the clinical trial experience and ease participation in clinical research for both patients and healthcare professionals. The alliance aims to create faster, improved access and connectivity to clinical trials for patients, with the ultimate goal of better experiences and outcomes.
“Pfizer is dedicated to increasing access to biosimilars for patients suffering from serious illnesses and helping create a more sustainable healthcare system,” said Andreas Penk, M.D., regional president, Oncology International Developed Markets at Pfizer.
BALTIMORE, Feb. 19, 2019 /PRNewswire/ -- Gliknik Inc. today announced that it will receive a $15 million milestone payment from Pfizer Inc. (PFE) following the start of a Phase I clinical trial of Pfizer drug candidate PF-06755347, previously known as GL-2045, for the potential treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disorder. Gliknik and Pfizer entered into an exclusive worldwide licensing agreement in 2013.
NEW YORK and INDIANAPOLIS, Feb. 19, 2019 /PRNewswire/ -- Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP). In this study, CLBP was defined as low back pain that had persisted for more than three consecutive months. On average, they had CLBP for 10 years, and they reported a significant impact of their pain on their ability to function in everyday life.
NEW BRUNSWICK, N.J. , Feb. 14, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, Feb. 28 th , at Lotte New York ...
NEW BRUNSWICK, N.J., Feb. 13, 2019 /PRNewswire/ -- Focused on creating the next frontier of surgery, Johnson & Johnson (JNJ), today announced that Ethicon, Inc., entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4 billion in cash. Auris Health is a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures.
Not intended for UK-based media ROCKLAND, Massachusetts and NEW YORK , Feb. 11, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada , ...
Data to be presented at the 2019 Genitourinary Cancers Symposium NEW YORK and TOKYO , Feb. 11, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...
NEW BRUNSWICK, N.J. , Feb. 5, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2019 CAGNY Conference on Tuesday, Feb. 19 , at The Boca Raton Resort, Boca Raton , FL. Alison Lewis ...
TECNIS Eyhance IOL is the latest innovation in the industry leading TECNIS® Family of Intraocular Lenses First lens (1) in the monofocal IOL category in Europe to deliver improved intermediate vision and ...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Johnson & Johnson (“J&J”) (JNJ). The Company has been embroiled in significant litigation by over 11,000 consumers claiming that its iconic talc powder products contained asbestos that caused cancer. Some cases have resulted in massive verdicts against J&J including a $417 million award to one California plaintiff in August 2017 and a $4.7 billion award in Missouri to 22 plaintiffs in July 2018.
Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro® (dacomitinib) 45 mg, as monotherapy, be granted marketing authorization in the European Union (EU) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. The CHMP’s opinion will now be reviewed by the European Commission (EC). Vizimpro was approved by the U.S. Food and Drug Administration (FDA) in 2018 for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain. The tanezumab 5 mg treatment arm met all three co-primary endpoints at 24 weeks, demonstrating a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA compared to those receiving placebo. The tanezumab 2.5 mg treatment arm met two of the three protocol-defined co-primary efficacy endpoints compared to placebo, demonstrating a statistically significant improvement in pain and physical function, while patients’ overall assessment of their OA was not statistically different than placebo.
2018 Fourth-Quarter Sales of $20.4 Billion increased 1.0%; EPS was $1.12 2018 Full-Year Sales of $81.6 Billion increased 6.7%, Full-Year EPS was $5.61 Adjusted 2018 Fourth-Quarter EPS was $1.97 , an increase ...
NEW ORLEANS , Jan. 18, 2019 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF ...
NEW BRUNSWICK, N.J., Jan. 17, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that Janssen Pharmaceuticals, Inc., member of the Johnson & Johnson Family of Companies, entered into a research study in collaboration with Apple Inc. to investigate whether a new heart health program using an app from Johnson & Johnson in combination with Apple Watch's irregular rhythm notifications and ECG app can accelerate the diagnosis and improve health outcomes of the 33 million people worldwide living with atrial fibrillation (AFib), a condition that can lead to stroke and other potentially devastating complications.
NEW BRUNSWICK, New Jersey, Jan. 17, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced the completion of the acquisition of Ci:z Holdings Co., Ltd. (4924.T) (the "Company") for a total purchase price of approximately ¥230 billion. The acquisition was completed through a series of transactions that included an all-cash tender offer to acquire publicly held shares of the Company for ¥5,900 per share. Johnson & Johnson plans to acquire the remaining shares of the Company that were not tendered in the tender offer through a share consolidation under Japanese law during the first half of 2019 and take appropriate actions to delist the Company from the Tokyo Stock Exchange. The Company, which markets the DR.
—FDA grants a Priority Review based on Phase 3 ATTR-ACT study findings in ATTR-CM—
Zamansky LLC investigates Johnson & Johnson Inc. (JNJ) (“J&J” or the “Company”) on behalf of its current and former employees for potential violations of the federal Employee Retirement Income Security Act (“ERISA”) in the J&J Savings Plan (the “Plan”). Zamansky LLC is a leading stock law firm with a practice in securities fraud, ERISA and employment class actions.
NEW BRUNSWICK, N.J. , Jan. 11, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) received notice of an unsolicited "mini-tender" offer by Peer & Peri LLC (Peer & Peri) to purchase up to 30,000 ...
NEW BRUNSWICK, N.J., Jan. 11, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that the conditions to its public tender offer for all of the outstanding shares of Ci:z Holdings Co., Ltd. (4924.T) (the "Company") not already held by Johnson & Johnson or its affiliates that was previously announced on October 23, 2018, have been satisfied and the offering period for the tender offer has expired.
NEW BRUNSWICK, N.J. , Jan. 10, 2019 /PRNewswire/ -- Nominations are now being accepted for the 2019 Dr. Paul Janssen Award for Biomedical Research. This prestigious award celebrates today's most dedicated ...